Novel strategies with bi-specific immunoconjugate constructs are focused on simultaneous targeting of NKG2D ligands, like MICA or ULBP1/2, and tumor-expressed antigens such as BCMA, CD19, and VEGFR2 [87]. The gene discussed is KLRK1; the disease is neoplasm.